Fosrenol for Enhancing Dietary Protein Intake in Hypoalbuminemic Dialysis Patients (FrEDI) Study

NACompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

February 29, 2012

Conditions
End-Stage Renal Disease
Interventions
OTHER

Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus

Based on the hypothesis that the efficacy and potency of Fosrenol enables increasing dietary protein intake and provision of meals during dialysis treatment for improving nutritional status in malnourished dialysis patients with a low serum albumin (\<4.0 g/dL) while serum phosphorus can be effectively controlled with the target range of 3.5 to 5.5 mg/dL

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

DaVita, Inc.

INDUSTRY

collaborator

Shire

INDUSTRY

lead

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

OTHER